{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:50:35Z","timestamp":1794952235068,"version":"4.9.1"},"reference-count":46,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2004,4,29]],"date-time":"2004-04-29T00:00:00Z","timestamp":1083196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Lumiracoxib (Prexige; Novartis Pharma AG, Basel, Switzerland) is a cyclooxygenase\u20102 selective inhibitor associated with improved gastrointestinal safety compared with nonsteroidal anti\u2010inflammatory drugs, in patients with osteoarthritis.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To compare the gastroduodenal safety of lumiracoxib with ibuprofen and celecoxib in patients with rheumatoid arthritis.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002A total of 893 patients with rheumatoid arthritis were randomized to lumiracoxib 400\u2003mg once daily, lumiracoxib 800\u2003mg once daily, ibuprofen 800\u2003mg three times daily or celecoxib 200\u2003mg twice daily for 13\u2003weeks, in a double\u2010blind randomised controlled clinical trial. The primary endpoint was the cumulative incidence of gastroduodenal ulcers over 13\u2003weeks.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002The incidence of gastroduodenal ulcers \u22653\u2003mm with lumiracoxib 400\u2003mg once daily (2.8%) or lumiracoxib 800\u2003mg once daily (4.3%) was significantly lower than with ibuprofen (13.6%, all <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) and not different from celecoxib (1.9%). The incidence of adverse events was similar for lumiracoxib 400, 800\u2003mg and celecoxib (78, 75 and 77%, respectively) and higher with ibuprofen (86%). Discontinuation for adverse events was highest for ibuprofen (12.5% vs. 7.9\u20138.8% for the other groups).<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002Lumiracoxib demonstrated gastroduodenal safety superior to ibuprofen and similar to celecoxib in patients with rheumatoid arthritis.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.01956.x","type":"journal-article","created":{"date-parts":[[2004,5,19]],"date-time":"2004-05-19T11:45:53Z","timestamp":1084967153000},"page":"1189-1198","source":"Crossref","is-referenced-by-count":44,"title":["Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis"],"prefix":"10.1111","volume":"19","author":[{"given":"A. J.","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nayiager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schimansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gimona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hawkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,4,29]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(97)80011-8"},{"issue":"1","key":"e_1_2_17_3_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/41.S1.3","article-title":"The prevalence and burden of arthritis","volume":"41","author":"Reginster JY.","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381002"},{"key":"e_1_2_17_5_2","first-page":"1","article-title":"National Ambulatory Medical Care Survey: 1989 summary","volume":"13","author":"Schappert SM.","year":"1992","journal-title":"Vital Health Stat"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.2.147"},{"key":"e_1_2_17_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90185-6"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91843-0"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00072-2"},{"issue":"51","key":"e_1_2_17_12_2","first-page":"8","article-title":"NSAID induced gastrointestinal complications: The ARAMIS perspective","volume":"25","author":"Singh G","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059991-00003"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00091-6"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/newbio231232a0"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320102"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V"},{"key":"e_1_2_17_18_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.1.2.3111928"},{"key":"e_1_2_17_19_2","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/S0021-9258(18)53294-4","article-title":"Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non\u2010steroidal anti\u2010inflammatory drugs","volume":"268","author":"Meade EA","year":"1993","journal-title":"J Biol Chem"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7563"},{"issue":"1","key":"e_1_2_17_21_2","first-page":"242","article-title":"Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects","volume":"61","author":"Scott G","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"e_1_2_17_22_2","first-page":"128","article-title":"Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis","volume":"61","author":"Scott G","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_17_23_2","first-page":"123","volume-title":"European collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics","author":"Reynolds C","year":"2003"},{"issue":"9","key":"e_1_2_17_24_2","first-page":"1616","article-title":"Efficacy and safety of COX189 in osteoarthritis: a multi\u2010national study","volume":"43","author":"Schnitzer TJ","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"e_1_2_17_25_2","first-page":"270","article-title":"Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4\u2003weeks of treatment: results from a randomized, placebo\u2010controlled trial","volume":"62","author":"Benevolenskaya L","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"e_1_2_17_26_2","first-page":"263","article-title":"Lumiracoxib is effective and well tolerated in patients with osteoarthritis of the hand: results from a randomized, placebo\u2010controlled trial","volume":"62","author":"Grifka J","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"e_1_2_17_27_2","first-page":"259","article-title":"The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX\u20102","volume":"61","author":"Marshall PJ","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_17_28_2","first-page":"123","volume-title":"European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics","author":"Scott G","year":"2003"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00318-5"},{"issue":"9","key":"e_1_2_17_30_2","first-page":"242","article-title":"Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: results of a randomized double\u2010blind study","volume":"48","author":"Geusens P","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"9","key":"e_1_2_17_31_2","first-page":"S212","article-title":"Lumiracoxib (Prexige) is effective in the treatment of osteoarthritis of the knee: a 13\u2010week, placebo\u2010controlled, active\u2010comparator, double\u2010blind study","volume":"46","author":"Tannenbaum H","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"e_1_2_17_32_2","first-page":"126","article-title":"Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189, compared with ibuprofen in osteoarthritis patients","volume":"61","author":"Hawkey CJ","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01691.x"},{"key":"e_1_2_17_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03740.x"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70334-3"},{"key":"e_1_2_17_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.619"},{"key":"e_1_2_17_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_17_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J"},{"key":"e_1_2_17_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(75)73812-9"},{"key":"e_1_2_17_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_17_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1921"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.6.820"},{"key":"e_1_2_17_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D"},{"key":"e_1_2_17_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1929"},{"key":"e_1_2_17_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00894.x"},{"key":"e_1_2_17_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(97)80048-0"},{"key":"e_1_2_17_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07598.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.01956.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.01956.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.01956.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:52:52Z","timestamp":1697194372000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.01956.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,29]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1111\/j.1365-2036.2004.01956.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.01956.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,29]]}}}